Psoriasis Genetic Markers and SNP Detection Methods

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods lack reliable genetic markers for diagnosing and treating psoriasis, as existing studies have not consistently identified effective markers for disease susceptibility and treatment response.

Innovation Solution

Identification of novel single nucleotide polymorphisms (SNPs) associated with psoriasis, along with methods for detecting these SNPs and using them to develop diagnostic reagents and therapeutic agents, allowing for personalized treatment strategies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current genetic marker studies are used for psoriasis diagnosis, then diagnostic methods are available, but the markers lack reliability and consistency

Engineering Contradiction:

Improvereliability of genetic markersVSAvoidconsistency of marker identification

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent segments the complex psoriasis genetic analysis into specific manageable SNP loci (IL12B, IL23R, and other identified polymorphisms). By focusing on discrete, well-defined genetic markers rather than broad genomic regions, the patent achieves more reliable and consistent diagnostic measurements while maintaining the ability to detect psoriasis susceptibility.

Inventive Principle:

Principle #1Segmentation

2Reliability

If generic psoriasis treatment is applied, then treatment can be provided, but treatment efficacy is suboptimal and side effects increase

Engineering Contradiction:

Improvetreatment efficacyVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by tailoring treatment to the specific genetic profile of each patient. By identifying particular SNP variants (such as IL12B rs3212227 and IL23R rs7530511) that predict treatment response, the patent enables clinicians to select therapies targeted to the patient's specific genetic characteristics, thereby improving efficacy while reducing exposure to ineffective treatments and their associated side effects.

Inventive Principle:

Principle #3Local quality

3Loss of time

If early detection methods are implemented, then psoriasis risk can be identified, but reliable genetic markers are currently lacking

Engineering Contradiction:

Improveearly detection timingVSAvoidavailability of genetic markers

Core Design Contradiction:

Loss of timeVSReliability

Solution Approach 1:

The patent enables preliminary action by identifying genetic markers (SNPs in IL12B, IL23R, and other genes) that predict psoriasis susceptibility before clinical symptoms manifest. By detecting these genetic variants in advance, the patent allows for early intervention and prevention strategies to be implemented before the disease develops or progresses, thereby reducing future health burdens.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS10920276B2Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof

Publication Date: 2021.02.16 CELERA CORP

AI summary

The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.